代谢功能障碍的临床过程和预测因素 与肥胖儿童和青少年的肥胖性肝病相关
R Narayanan1, Vibha Yadav1, Jaya Agarwal2
1Departments of Pediatric Endocrinology, Regency Hospital Limited, Uttar Pradesh, Kanpur, India.
Indian pediatrics
|February 17, 2026
概括
小儿代谢功能障碍相关的脂肪性肝病 (MASLD) 显示出不同的结果. 在患有MASLD的儿童中实现缓解与降低他们的体重指数 (BMI) Z-score有显著联系.
科学领域:
- 儿科肝病学 儿科肝病学
- 代谢障碍 代谢障碍 代谢障碍
- 肝脏疾病研究 肝脏疾病研究
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 在儿童中越来越普遍.
- 了解儿童群体中MASLD的长期过程和预测因素对于有效管理至关重要.
研究的目的:
- 为了研究儿科MASLD的临床过程.
- 为了确定治疗结果的预测因素,特别是缓解,在患有MASLD的儿童.
主要方法:
- 对100名被诊断患有MASLD的肥胖儿童进行了回顾性审查.
- 在随访期间分析身体质量指数 (BMI) Z-score 和氨酸转移酶 (ALT) 水平的变化.
主要成果:
- 在100名被跟踪2年的儿童中,72%的ALT正常化.
- 持续缓解 (55%) 与BMI Z-score (P < 0.001) 的较大降低密切相关.
- 降低的BMI Z-score是缓解的唯一预测因素 (OR 6.67;P = 0.007).
结论:
- 儿科MASLD表现出一个可变的疾病过程.
- 降低BMI Z-分数是预测儿科MASLD缓解的关键因素.
- 13.8%的BMI Z-score降低被确定为缓解的预测指标.
相关概念视频
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
199
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
199
Obesity
1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Overview of Lipid Metabolism
5.8K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
5.8K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
302
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
302
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
212
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212
Pharmacokinetics in Pediatric Patients: Drug Metabolism
258
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
258


